Genmab — Maj 2019
-
Bliver udgift bomber, så der er brug for 3 mia mere.
-
JVW sagde jo netop at de ville tage det største spring på udgiftssiden iår. Og at der ikke bliver tilsvarende stigninger de næste år
-
Der er noget, der ikke passer. Forhåbentlig til den gode side (det vælger jeg at tror på). Det ville være utroværdigt så det skriger mod himlen hvis de guider stort spring i udgiftssiden med negativt nettoresultat for 2020-2021
-
Så skulle det være at ingen vil være med til 50/50 partnerskab og at de der bliver nødt til at finansiere det hele selv
-
Tænker dog stadig at udvidelsen kommer tidligt og er meget lille til det formål
-
It must be a repetition.
-
I 2017 var det 230 dage. http://www.pharmexec.com/how-fast-are-fda-fast-lanes
-
ASCO – AMG 510 is obviously the most interesting program but it will be hard to meet expectations. Other than that couldn’t find anything earth shattering in the abstracts. There should be an update on BCMA bispecifics, I found JNJ’s EGFR/MET bsAb intriguing but efficacy wasn’t stellar. Looking forward to seeing SGEN’s Nectin4 data in bladder cancer as well.
-
-
hvis MAIA fejler er dette ikke nok, det er stensikkert
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind